hotspot -WSS

hotspot

author：hotspot 2025-09-27 12:36:04 - browse：5

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Why health care costs have stayed mostly flat since 2010

hotspot

WSS

HCA sued by state AG for quality issues at Mission Health

Carvykti CAR

CRISPR gene editing developments we’re watching in 2024

Cholera vaccine supply gets boost as demand surges globally

Cholera vaccine supply gets boost as demand surges globally

Getting Alzheimer's drug Leqembi to patients can be a challenge

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

New air purifier tech could be key to improving indoor air quality

H5N1 bird flu virus started spreading in cows in Texas in December

Hollywood unions extend contract negotiations for actors

CRISPR gene editing developments we’re watching in 2024

Guidelines to prevent youth baseball injuries need more muscle

Cue Health's Covid

Guidelines to prevent youth baseball injuries need more muscle

Getting Alzheimer's drug Leqembi to patients can be a challenge

Alkermes shareholders re

MultiPlan and major insurers sued for alleged medical price

knowledge

Grail spinoff by Illumina should end disastrous merger attempt

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Carvykti CAR

Cue Health's Covid

Exact Sciences stock tumbles despite strong cancer detection sales

Why health care costs have stayed mostly flat since 2010

leisure time

focus

hotspot

hotspot